An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus.

ABSTRACT:

Purpose of review

Sodium-glucose co-transporter-2 (SGLT2) inhibitors are the newest class of oral antihyperglycemic agents that have been approved for the treatment of diabetes mellitus. Over the past year, there have been significant developments in both the safety and efficacy of this class of medications that are presented in this review.

Recent findings

Apart from data on the glucose-lowering effect of SGLT2 inhibitors, other metabolic benefits have been demonstrated for this class of medications. Moreover, there have been three Food and Drug Administration Drug Safety Communications issued in 2015 that have led to additional drug labeling. The basic mechanism of action, indications, glucose-lowering benefits, other metabolic benefits, and adverse side-effects of SGLT2 i

SUBMITTER: Hsia DS 

PROVIDER: S-EPMC6028052 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature